# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Interferon beta-1a (Rebif)

#### Notes:

\* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

<u>Initiation (new start) criteria</u>: Non-formulary **interferon beta-1a (Rebif)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a Neurologist
- Diagnosis of Relapsing form of Multiple Sclerosis (MS) on the Problem list, including:
  - Non-Progressive Relapsing MS
  - o Progressive Relapsing MS
  - Relapsing Remitting MS
- Patient has an allergy or is intolerance\* to
  - Glatiramer acetate (Copaxone or Glatopa) AND
  - Interferon-beta1b (Extavia)

<u>Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously</u>: Non-formulary interferon beta-1a (Rebif) will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Prescribed by a Neurologist
- Diagnosis of Multiple Sclerosis (MS) on the Problem list
- Patient has an allergy or is intolerance\* to
  - o Glatiramer acetate (Copaxone or Glatopa) AND
  - Interferon-beta1b (Extavia)

<u>Criteria for new members entering Kaiser Permanente already taking the</u> <u>medication who have not been reviewed previously</u>. Non-formulary <u>interferon beta-1a (Rebif)</u> will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Diagnosis of Multiple Sclerosis (MS)
- Patient has an allergy or is intolerance\* to
  - Glatiramer acetate (Copaxone or Glatopa) AND
  - Interferon-beta1b (Extavia)

kp.org

Revised: 10/10/19 Effective: 11/07/19 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



## Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Interferon beta-1a (Rebif)

<u>Continued use criteria for patients stable on the medication:</u> Non-formulary **interferon beta-1a (Rebif)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a Neurologist
- Patient has completed the following labs within the last 6 months:
  - Complete blood count with differential (CBC w/ diff)
  - Liver function test (alanine aminotransferase, ALT)
- Patient is NOT using interferon beta-1a (Rebif) with another disease modifying treatment (i.e., glatiramer, interferon beta-1b, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, rituximab)

kp.org

Revised: 10/10/19 Effective: 11/07/19



